Celsius Soars 33% on Strong Q4 Earnings, $1.65B Alani Nu Deal; Neurocrine Biosciences Approves $500M Share Buyback; Intra-Cellular Therapies Reports 47% CAPLYTA Sales Surge, FDA sNDA Acceptance.
Market-Moving Event Alerts
Remember to move the mail to the Primary inbox if this mail is in other inboxes.
This week, StockNews.AI delivered 223 successful event alerts across multiple sectors, with nearly 20% of them driving price surges of over 10%!
Even more impressive, we've maintained this streak for two consecutive weeks —proving the power of our AI-driven insights.
*Data Captured Between 2/17 00:00am - 2/21 11:00 am EDT.
*Penny stocks are excluded from the 10%+ price change analysis. *Please note that the stock market was closed on 2/17 due to President’s Day.
Top 3 AI Events you can’t miss for today, 2/21.
CNBC
VeryBullishLongTermCELHM&A
Energy drink stock Celsius pops more than 30% on big quarterly results, Alani Nu acquisition
- Record Q4 revenue of $332.2M beat analyst expectations. Earnings exceeded forecasts.
- Acquisition of Alani Nutrition for $1.65B drives growth. Deal integrates two strong brands.
- Premarket shares surged over 33% amid short squeeze dynamics. Investor sentiment is upbeat.
- Historical 58% decline over 12 months contrasts with current rebound. Recovery signals are emerging.
PRNewsWire
BullishShortTermNBIXShares Buyback
Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program
- NBIX board approves a new $500M share repurchase program. It is subject to market conditions.
- The repurchase adds to a prior $300M accelerated buyback completed in early February 2025.
- The program permits various methods including open-market trades and pre-set plans.
- Capital allocation focuses on commercial products, INGREZZA and CRENESSITY, and R&D investments.
GlobeNewsWire
VeryBullishLongTermITCIEarnings
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results
- CAPLYTA full year sales hit $680.5M, a 47% increase year-over-year.
- Q4 CAPLYTA sales reached $199.2M, growing 51% from last year.
- FDA accepted the lumateperone sNDA for adjunctive MDD treatment, boosting prospects.
- Sales force expansion and multiple late-stage trials underscore a deepening pipeline.
Here’re the top 5 most-surged stocks captured by our AI Event signal this week.
*Penny stocks are not included in the list.
PRNewsWire
BullishShortTerm 38.85%NAASShares Buyback
NaaS Technology Inc. Announces US$10 Million Share Repurchase Program
- Board approves $10M share repurchase program for ADS shares.
- Program effective Feb 21, 2025 and runs for 12 months.
- Repurchases may occur via open market, block trades, or private deals.
- Press release emphasizes forward-looking statements and operational risks.
GlobeNewsWire
BullishLongTerm 32.23%LUNGEarnings
Pulmonx Reports Record Fourth Quarter and Full Year 2024 Financial Results
- Pulmonx's 2024 revenue reached $83.8M, a 22% annual increase.
- Q4 2024 revenue hit $23.8M, up 23% year-over-year.
- U.S. revenue in 2024 rose to $56.5M, a 23% growth.
- Gross margin remained strong at 74% for both Q4 and full year.
CNBC
VerybullishLongTerm 29.3%CELHM&A
Energy drink stock Celsius pops more than 30% on big quarterly results, Alani Nu acquisition
- Record Q4 revenue of $332.2M beat analyst expectations. Earnings exceeded forecasts.
- Acquisition of Alani Nutrition for $1.65B drives growth. Deal integrates two strong brands.
- Premarket shares surged over 33% amid short squeeze dynamics. Investor sentiment is upbeat.
- Historical 58% decline over 12 months contrasts with current rebound. Recovery signals are emerging.
PRNewsWire
BullishLongTerm 28.56%COMPEarnings
Compass, Inc. Reports Fourth Quarter and Full-Year 2024 Results
- Compass revenue in Q4 increased 25.9% YoY, signaling strong growth.
- Operating cash flow reached $30.5 million, indicating effective cash management.
- Market share grew to 5.06%, the largest increase in 12 quarters.
- Positive outlook for Q1 2025 with projected revenue between $1.35B-$1.475B.
- Compass expects to capture greater market share as the industry recovers.
GlobeNewsWire
BullishLongTerm 26.95%PRFXM&A
PainReform Executes Definitive Agreement to Acquire DeepSolar, Marking a Unique Expansion Opportunity
- PainReform acquires DeepSolar for strategic growth in solar analytics.
- DeepSolar enhances solar asset management with AI-driven solutions.
- Acquisition expected to close by February 2025, pending conditions.
- DeepSolar targets both large operators and residential solar users.
- The solar market grows at an impressive annual rate of 25.32%.
Want to see customized event news?
Subscribe and Activate Event Alert Today!
Disclaimer: The content provided in this Email should be used for informational purposes only and in no way should be relied upon for financial advice.
Reply